Axsome Therapeutics, Inc. (AXSM)

Axsome is a New York-based biotech company in the business of developing and commercializing drugs for conditions affecting the central nervous system—depression, excessive daytime sleepiness, migraine, and neurodegenerative disorders. Unlike many preclinical-stage biotechs burning cash, Axsome has moved past that phase; it now has three FDA-approved drugs on the market and a growing revenue base.

The company made its name with Auvelity, a dextromethorphan-bupropion combination approved for major depressive disorder in 2024. That approval was a breakthrough for Axsome because it was the first new oral antidepressant mechanism in decades, and it came after the company had faced significant setbacks earlier in its pipeline. Auvelity also won approval in 2026 for agitation associated with dementia due to Alzheimer’s disease, expanding its addressable market. The drug has strong commercial uptake and generated a meaningful portion of the company’s recent revenue.

Beyond Auvelity, Axsome markets Sunosi (viloxazine) for excessive daytime sleepiness—a narrower indication but one with solid payer coverage—and SYMBRAVO (meloxicam and rizatriptan), approved in early 2025 for acute migraine treatment. That three-drug portfolio has lifted Axsome from a story stock into an actual operating company with recognizable sales momentum.

The company’s structure is straightforward: it identifies unmet needs in neuroscience and psychiatry, licenses or develops drugs to address them, runs the trials, pursues FDA approval, and then sells to patients and payers. It works with established pharma partners on marketing and distribution. Axsome does not manufacture; it depends on contract manufacturers for production.

Main approved products:

• Auvelity (major depressive disorder, agitation in Alzheimer’s)
• Sunosi (excessive daytime sleepiness)
• SYMBRAVO (migraine)

The competitive field in CNS is crowded, but Axsome has positioned itself as a specialist in novel mechanisms and smaller, underserved conditions rather than chasing massive blockbuster categories. That focus has worked so far, turning the company into a credible mid-cap biotech with genuine revenue and a clinical pipeline worth monitoring.